Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05187832
Study type Interventional
Source Kind Pharmaceuticals LLC
Contact Yusha Zhu, MD PhD
Phone 6467252552
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date March 2022
Completion date May 2025

See also
  Status Clinical Trial Phase
Completed NCT00748553 - A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT01625286 - Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients Phase 1/Phase 2
Recruiting NCT04742153 - A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) Phase 2
Completed NCT02154776 - Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Phase 1
Recruiting NCT04494425 - Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Phase 3
Recruiting NCT03767335 - MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer Phase 1
Active, not recruiting NCT01676753 - Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer Phase 1
Active, not recruiting NCT01226316 - Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase 1